157 related articles for article (PubMed ID: 11695547)
1. Xpa and Xpa/p53+/- knockout mice: overview of available data.
van Kreijl CF; McAnulty PA; Beems RB; Vynckier A; van Steeg H; Fransson-Steen R; Alden CL; Forster R; van der Laan JW; Vandenberghe J
Toxicol Pathol; 2001; 29 Suppl():117-27. PubMed ID: 11695547
[TBL] [Abstract][Full Text] [Related]
2. DNA repair-deficient Xpa and Xpa/p53+/- knock-out mice: nature of the models.
van Steeg H; de Vries A; van Oostrom CTh ; van Benthem J; Beems RB; van Kreijl CF
Toxicol Pathol; 2001; 29 Suppl():109-16. PubMed ID: 11695546
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol.
Lina BA; Woutersen RA; Bruijntjes JP; van Benthem J; van den Berg JA; Monbaliu J; Thoolen BJ; Beems RB; van Kreijl CF
Toxicol Pathol; 2004; 32(2):192-201. PubMed ID: 15200157
[TBL] [Abstract][Full Text] [Related]
4. P53+/- hemizygous knockout mouse: overview of available data.
Storer RD; French JE; Haseman J; Hajian G; LeGrand EK; Long GG; Mixson LA; Ochoa R; Sagartz JE; Soper KA
Toxicol Pathol; 2001; 29 Suppl():30-50. PubMed ID: 11695560
[TBL] [Abstract][Full Text] [Related]
5. Use of DNA repair-deficient XPA transgenic mice in short-term carcinogenicity testing.
van Steeg H; Klein H; Beems RB; van Kreijl CF
Toxicol Pathol; 1998; 26(6):742-9. PubMed ID: 9864090
[TBL] [Abstract][Full Text] [Related]
6. Deregulation of cancer-related pathways in primary hepatocytes derived from DNA repair-deficient Xpa-/-p53+/- mice upon exposure to benzo[a]pyrene.
van Kesteren PC; Zwart PE; Pennings JL; Gottschalk WH; Kleinjans JC; van Delft JH; van Steeg H; Luijten M
Toxicol Sci; 2011 Sep; 123(1):123-32. PubMed ID: 21715664
[TBL] [Abstract][Full Text] [Related]
7. Detection of genotoxic and non-genotoxic carcinogens in Xpc(-/-)p53(+/-) mice.
Melis JP; Speksnijder EN; Kuiper RV; Salvatori DC; Schaap MM; Maas S; Robinson J; Verhoef A; van Benthem J; Luijten M; van Steeg H
Toxicol Appl Pharmacol; 2013 Jan; 266(2):289-97. PubMed ID: 23153559
[TBL] [Abstract][Full Text] [Related]
8. CB6F1-rasH2 mouse: overview of available data.
Usui T; Mutai M; Hisada S; Takoaka M; Soper KA; McCullough B; Alden C
Toxicol Pathol; 2001; 29 Suppl():90-108. PubMed ID: 11695565
[TBL] [Abstract][Full Text] [Related]
9. Neonatal mouse model: review of methods and results.
McClain RM; Keller D; Casciano D; Fu P; MacDonald J; Popp J; Sagartz J
Toxicol Pathol; 2001; 29 Suppl():128-37. PubMed ID: 11695548
[TBL] [Abstract][Full Text] [Related]
10. A perspective on current and future uses of alternative models for carcinogenicity testing.
Goodman JI
Toxicol Pathol; 2001; 29 Suppl():173-6. PubMed ID: 11695554
[TBL] [Abstract][Full Text] [Related]
11. Effect of heterozygous loss of p53 on benzo[a]pyrene-induced mutations and tumors in DNA repair-deficient XPA mice.
van Oostrom CT; Boeve M; van Den Berg J; de Vries A; Dollé ME; Beems RB; van Kreijl CF; Vijg J; van Steeg H
Environ Mol Mutagen; 1999; 34(2-3):124-30. PubMed ID: 10529736
[TBL] [Abstract][Full Text] [Related]
12. DNA repair-deficient Xpa/p53 knockout mice are sensitive to the non-genotoxic carcinogen cyclosporine A: escape of initiated cells from immunosurveillance?
van Kesteren PC; Beems RB; Luijten M; Robinson J; de Vries A; van Steeg H
Carcinogenesis; 2009 Mar; 30(3):538-43. PubMed ID: 19136475
[TBL] [Abstract][Full Text] [Related]
13. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
Cohen SM
Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
[TBL] [Abstract][Full Text] [Related]
14. Finding transcriptomics biomarkers for in vivo identification of (non-)genotoxic carcinogens using wild-type and Xpa/p53 mutant mouse models.
Jonker MJ; Bruning O; van Iterson M; Schaap MM; van der Hoeven TV; Vrieling H; Beems RB; de Vries A; van Steeg H; Breit TM; Luijten M
Carcinogenesis; 2009 Oct; 30(10):1805-12. PubMed ID: 19696161
[TBL] [Abstract][Full Text] [Related]
15. Phenacetin acts as a weak genotoxic compound preferentially in the kidney of DNA repair deficient Xpa mice.
Luijten M; Speksnijder EN; van Alphen N; Westerman A; Heisterkamp SH; van Benthem J; van Kreijl CF; Beems RB; van Steeg H
Mutat Res; 2006 Apr; 596(1-2):143-50. PubMed ID: 16464479
[TBL] [Abstract][Full Text] [Related]
16. Tg.AC genetically altered mouse: assay working group overview of available data.
Eastin WC; Mennear JH; Tennant RW; Stoll RE; Branstetter DG; Bucher JR; McCullough B; Binder RL; Spalding JW; Mahler JF
Toxicol Pathol; 2001; 29 Suppl():60-80. PubMed ID: 11695563
[TBL] [Abstract][Full Text] [Related]
17. Assessment of carcinogenicity of di(2-ethylhexyl)phthalate in a short-term assay using Xpa-/- and Xpa-/-/p53+/- mice.
Mortensen A; Bertram M; Aarup V; Sørensen IK
Toxicol Pathol; 2002; 30(2):188-99. PubMed ID: 11950162
[TBL] [Abstract][Full Text] [Related]
18. Alternative models for carcinogenicity testing.
Cohen SM; Robinson D; MacDonald J
Toxicol Sci; 2001 Nov; 64(1):14-9. PubMed ID: 11606797
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the levels of enzymes involved in drug metabolism between transgenic or gene-knockout and the parental mice.
Ariyoshi N; Imaoka S; Nakayama K; Takahashi Y; Fujita K; Funae Y; Kamataki T
Toxicol Pathol; 2001; 29 Suppl():161-72. PubMed ID: 11695553
[TBL] [Abstract][Full Text] [Related]
20. p53 heterozygosity results in an increased 2-acetylaminofluorene-induced urinary bladder but not liver tumor response in DNA repair-deficient Xpa mice.
Hoogervorst EM; van Oostrom CT; Beems RB; van Benthem J; Gielis S; Vermeulen JP; Wester PW; Vos JG; de Vries A; van Steeg H
Cancer Res; 2004 Aug; 64(15):5118-26. PubMed ID: 15289314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
